MedWatch

Janssen secretive about Ebola collaboration with Bavarian

The Ebola virus is once again in the public eye, but Janssen keeps its cards close to the chest regarding the company's Ebola candidate that is developed together with Bavarian Nordic.

Foto: Ritzau Scanpix/AFP/John Wessels

A new Ebola outbreak in the Democratic Republic of Congo has brought new attention to the deadly tropical disease.

But this time, the authorities have a new weapon to combat the virus: Merck's rVSV-ZEBOV vaccine is utilized for the first time and has won widespread attention. However, there is not much new about the rival from Janssen.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier